{"id":1564,"date":"2025-03-12T11:32:47","date_gmt":"2025-03-12T10:32:47","guid":{"rendered":"https:\/\/remeds.org\/?p=1564"},"modified":"2025-05-20T23:55:18","modified_gmt":"2025-05-20T21:55:18","slug":"start-of-recruitment-for-the-attune-clinical-trial","status":"publish","type":"post","link":"https:\/\/remeds.org\/tr\/2025\/03\/12\/start-of-recruitment-for-the-attune-clinical-trial\/","title":{"rendered":"ATTUNE klinik \u00e7al\u0131\u015fmas\u0131 i\u00e7in hasta al\u0131m\u0131 ba\u015flad\u0131"},"content":{"rendered":"<p>\u00d6nc\u00fc nitelikteki ATTUNE klinik \u00e7al\u0131\u015fmas\u0131 i\u00e7in hasta al\u0131m\u0131 resmen ba\u015flad\u0131! \u0130lk merkez, Kas\u0131m 2024\u2019te ABD\u2019nin Teksas eyaletinde, Houston\u2019daki Baylor College of Medicine\u2019de a\u00e7\u0131larak Faz 1\/2 \u00e7al\u0131\u015fmas\u0131n\u0131n ba\u015flang\u0131c\u0131n\u0131 i\u015faret etti. Ocak 2025\u2019in sonunda ise ikinci merkez ABD\u2019nin Minnesota eyaletinde a\u00e7\u0131ld\u0131. Yak\u0131nda Amerika Birle\u015fik Devletleri\u2019nde ve d\u00fcnya genelinde ba\u015fka merkezlerin de a\u00e7\u0131lmas\u0131 bekleniyor.&nbsp;<\/p>\n\n\n\n<p><strong>Denemeye Genel Bak\u0131\u015f<\/strong>&nbsp;<\/p>\n\n\n\n<p>ATTUNE denemesi, ION440\u2019\u0131n ilk kez insanlarda uyguland\u0131\u011f\u0131 \u00e7al\u0131\u015fmad\u0131r. Ara\u015ft\u0131rma a\u015famas\u0131ndaki bu ASO tedavisi, MDS\u2019li bireylerde MECP2 mRNA seviyelerini azaltmay\u0131 ve b\u00f6ylece MECP2 a\u015f\u0131r\u0131 ifadesinden kaynaklanan semptomlar\u0131n temel nedenini hedeflemeyi ama\u00e7lamaktad\u0131r.&nbsp;<\/p>\n\n\n\n<p>Bu potansiyel tedavi yakla\u015f\u0131m\u0131, preklinik ara\u015ft\u0131rma deneylerinde etkileyici sonu\u00e7lar g\u00f6stermi\u015ftir. 2021 y\u0131l\u0131nda MDS fare modelleri \u00fczerinde yap\u0131lan \u00e7al\u0131\u015fmalar, ASO tedavisinin MECP2 seviyelerini etkili bir \u015fekilde azaltt\u0131\u011f\u0131n\u0131 ve hastal\u0131k semptomlar\u0131n\u0131 \u00f6nemli yan etkiler olmadan hafifletti\u011fini ortaya koymu\u015ftur. Yakla\u015f\u0131k 10 y\u0131l \u00f6nce elde edilen bu bulgular, MDS toplulu\u011fu i\u00e7inde b\u00fcy\u00fck bir heyecan ve umut yaratm\u0131\u015ft\u0131r.&nbsp;<\/p>\n\n\n\n<p><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33658357\/\" target=\"_blank\" rel=\"noreferrer noopener\">Yay\u0131na bak\u0131n\u0131z<\/a><\/p>\n\n\n\n<p>\u00c7al\u0131\u015fmaya, 2 ile 65 ya\u015f aras\u0131nda, MECP2 Duplikasyon Sendromu tan\u0131s\u0131 do\u011frulanm\u0131\u015f erkek kat\u0131l\u0131mc\u0131lar dahil edilmi\u015ftir. \u00c7al\u0131\u015fma 2 b\u00f6l\u00fcme ayr\u0131lacakt\u0131r. B\u00f6l\u00fcm 1 (Artan \u00e7oklu dozlar) her kat\u0131l\u0131mc\u0131 i\u00e7in 36 hafta s\u00fcrecektir. Bu a\u015famada, kat\u0131l\u0131mc\u0131lar rastgele \u015fekilde ya ION440 ya da sahte bir prosed\u00fcr alacakt\u0131r. B\u00f6l\u00fcm 1\u2019in tamamlanmas\u0131n\u0131n ard\u0131ndan, kat\u0131l\u0131mc\u0131 B\u00f6l\u00fcm 2\u2019ye (Uzun d\u00f6nem uzatma) ge\u00e7ebilir ve 156 haftaya kadar ION440 alabilir.&nbsp;&nbsp;<\/p>\n\n\n\n<p>Her kat\u0131l\u0131mc\u0131, ba\u015flang\u0131\u00e7 tarama d\u00f6nemi, ION440 uygulamas\u0131 ve potansiyel ila\u00e7 tedavisinin g\u00fcvenli\u011fi, tolere edilebilirli\u011fi ve \u00f6n etkinlik sonu\u00e7lar\u0131n\u0131 de\u011ferlendirmek i\u00e7in bir takip a\u015famas\u0131n\u0131 i\u00e7eren ayr\u0131nt\u0131l\u0131 bir programa uyacakt\u0131r. Kat\u0131l\u0131mc\u0131lar, her bir kohortun farkl\u0131 bir ION440 doz seviyesi alaca\u011f\u0131 \u015fekilde, farkl\u0131 kohortlara ard\u0131\u015f\u0131k olarak kaydedilecektir.&nbsp;&nbsp;<\/p>\n\n\n\n<p>\u00c7al\u0131\u015fma protokol\u00fc ve genel \u00e7al\u0131\u015fma tasar\u0131m\u0131 hakk\u0131nda daha fazla ayr\u0131nt\u0131 i\u00e7in sizi a\u015fa\u011f\u0131daki kaynaklar\u0131 incelemeye davet ediyoruz:&nbsp;<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>ATTUNE \u00e7al\u0131\u015fmas\u0131yla ilgili detaylar\u0131 a\u00e7\u0131klayan web seminerlerimiz:\u00a0<a href=\"https:\/\/dupmecp2.eu\/attune-study\/\">ATTUNE \u00c7al\u0131\u015fmas\u0131n\u0131 Anlamak<\/a><\/li>\n\n\n\n<li>\u00c7al\u0131\u015fma protokol\u00fcyle ilgili makalemiz:\u00a0<a href=\"https:\/\/dupmecp2.eu\/ion440\/\" target=\"_blank\" rel=\"noreferrer noopener\">IONIS, MDS toplulu\u011funu bir sonraki seviyeye ta\u015f\u0131yor<\/a>\u00a0<\/li>\n\n\n\n<li>Ailelerden gelen t\u00fcm soru cevaplar\u0131 i\u00e7eren e-kitab\u0131m\u0131z:\u00a0<a href=\"https:\/\/dupmecp2.eu\/attune-study\/\">ATTUNE \u00c7al\u0131\u015fmas\u0131n\u0131 Anlamak<\/a><\/li>\n<\/ul>\n\n\n\n<p><strong>Sonraki Ad\u0131mlar ve Hedefler<\/strong>&nbsp;<\/p>\n\n\n\n<p>Bir Faz 1\/2 klinik denemesi olarak ATTUNE\u2019un birincil amac\u0131, ION440\u2019\u0131n g\u00fcvenli\u011fini ve tolere edilebilirli\u011fini de\u011ferlendirmektir. ATTUNE denemesinden elde edilecek bulgular, ION440\u2019\u0131n MDS tedavisi olarak etkinli\u011fini daha ileri d\u00fczeyde de\u011ferlendirecek gelecekteki \u00e7al\u0131\u015fmalar i\u00e7in de\u011ferli bilgiler sa\u011flayacakt\u0131r.&nbsp;<\/p>\n\n\n\n<p>Houston\u2019daki Children\u2019s Hospital ve Minnesota\u2019daki Gillette Children\u2019s Specialty Healthcare ara\u015ft\u0131rma ekipleri, ara\u015ft\u0131rma a\u015famas\u0131ndaki tedavinin uygulanmas\u0131na ba\u015flamak \u00fczere \u015fu anda hasta kabul etmektedir.&nbsp;&nbsp;<\/p>\n\n\n\n<p><strong>ATTUNE klinik \u00e7al\u0131\u015fmas\u0131n\u0131n ba\u015flat\u0131lmas\u0131, MECP2 Duplikasyon Sendromu i\u00e7in tedavi aray\u0131\u015f\u0131nda ola\u011fan\u00fcst\u00fc bir ileri ad\u0131m\u0131 temsil etmektedir. HERO klinik \u00e7al\u0131\u015fmas\u0131na gelince, Antisense Oligon\u00fckleotid teknolojisinin yenilik\u00e7i kullan\u0131m\u0131 bu duruma y\u00f6nelik son teknoloji bir yakla\u015f\u0131m\u0131 ortaya koymakta ve ailelere ve MDS toplulu\u011funa yeniden umut sunmaktad\u0131r.<\/strong>&nbsp;<\/p>\n\n\n\n<p><a href=\"https:\/\/dupmecp2.eu\/recruitement-hero\/\"><\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>ATTUNE denemesi, Ionis taraf\u0131ndan desteklenen Faz 1\/2 klinik bir \u00e7al\u0131\u015fmad\u0131r. Bu \u00e7al\u0131\u015fman\u0131n amac\u0131, MECP2 Duplikasyon Sendromu\u2019nun (MDS) temel nedenini hedeflemek \u00fczere geli\u015ftirilen ara\u015ft\u0131rma a\u015famas\u0131ndaki bir Antisense Oligon\u00fckleotid (ASO) tedavisi olan ION440\u2019\u0131n de\u011ferlendirilmesidir. <\/p>","protected":false},"author":73,"featured_media":1570,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jf_save_progress":"","footnotes":""},"categories":[11,9],"tags":[],"class_list":["post-1564","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-aso","category-research"],"_links":{"self":[{"href":"https:\/\/remeds.org\/tr\/wp-json\/wp\/v2\/posts\/1564","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/remeds.org\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/remeds.org\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/remeds.org\/tr\/wp-json\/wp\/v2\/users\/73"}],"replies":[{"embeddable":true,"href":"https:\/\/remeds.org\/tr\/wp-json\/wp\/v2\/comments?post=1564"}],"version-history":[{"count":1,"href":"https:\/\/remeds.org\/tr\/wp-json\/wp\/v2\/posts\/1564\/revisions"}],"predecessor-version":[{"id":1565,"href":"https:\/\/remeds.org\/tr\/wp-json\/wp\/v2\/posts\/1564\/revisions\/1565"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/remeds.org\/tr\/wp-json\/wp\/v2\/media\/1570"}],"wp:attachment":[{"href":"https:\/\/remeds.org\/tr\/wp-json\/wp\/v2\/media?parent=1564"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/remeds.org\/tr\/wp-json\/wp\/v2\/categories?post=1564"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/remeds.org\/tr\/wp-json\/wp\/v2\/tags?post=1564"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}